Skip to main content
Premium Trial:

Request an Annual Quote

Diaxonhit, One Lambda Renew Distribution Partnership for Transplant Dx

NEW YORK (GenomeWeb) – Diaxonhit today announced that its affiliate InGen has renewed an exclusive deal to distribute One Lambda's transplantation diagnostic tests in France.

Financial and other details of the partnership were not disclosed.

Thermo Fisher Scientific's One Lambda develops and distributes several lines of HLA typing and antibody detection assays that use serological, molecular, ELISA, flow cytometry, and Luminex's xMap technologies. The tests are used to assess the compatibility between donor and recipient before transplantation, and to follow-up on transplanted patients by monitoring potential organ rejection.

Diaxonhit is an integrated in vitro diagnostics firm that distributes IVD products for transplantation, infectious diseases, and cancer to the French market.

Paris, France-based Diaxonhit was formed in 2012 when Exonhit acquired InGen Biosciences. Thermo Fisher acquired One Lambda, also in 2012.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.